Objectives: To assess the in vitro susceptibility of multidrug-resistant Enterobacteriaceae (MDRE) isolates to tigecycline.
Introduction
Tigecycline, a semi-synthetic derivative of minocycline, is a member of the tetracycline family and is the first glycylcycline available for clinical use. 1 In comparison with other tetracyclines, tigecycline displays a higher in vitro activity against several Gram-positive and a large variety of Gram-negative microorganisms, including multidrug-resistant strains.
Interpretive criteria for in vitro susceptibility testing of tigecycline are currently based either on the breakpoints approved by the FDA or on those published by EUCAST; 2 on the other hand, the CLSI has not yet released any tentative or approved guidelines. 3 Differences in susceptibility results according to the MIC interpretive criteria of the two guidelines 4 and also according to the testing methods used 5 have been underlined in several reports.
In this study, we investigated the in vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline by Vitek 2 (VTK) compared with the reference broth microdilution (BMD) method using the MIC interpretive criteria recommended in the 2011 EUCAST guidelines.
Methods

Bacterial isolates
A collection of 404 non-duplicate (one isolate per species per patient) extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae isolates with genotypically well-characterized mechanisms of resistance to b-lactams recovered from clinical specimens of patients collected in 91 hospital-based laboratories in 2010 6 were challenged for susceptibility to tigecycline. Further, 97 multidrug-resistant but not ESBL-producing Enterobacteriaceae isolates were also tested.
Confirmation of the identification of the isolates to species level was carried out centrally at our laboratory by the MALDI-TOF mass spectrometry method using the Microflex LT (Bruker Daltonik GmbH, Leipzig, Germany). ESBL production among these isolates was confirmed by # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 2696 -2699 doi:10.1093/jac/dks288 Advance Access publication 24 July 2012 using the disc diffusion method based on the criteria provided by the CLSI 3 and by PCR using a commercial microarray technology-based DNA test, the Check-KPC ESBL microarray (Check-Points Health BV, Wageningen, The Netherlands). 7 Escherichia coli ATCC 25922 was used as a quality control strain in each batch of MIC testing.
Procedure
Isolates stored at 2808C were thawed and subcultured overnight on blood agar plates before testing. MICs were determined by the CLSI reference BMD method using Sensititre w GNX2F panels (Trek Diagnostic Systems, Cleveland, OH, USA) and by the VTK automated system using AST-N156 cards (bioMérieux, Marcy l'Étoile, France), according to the manufacturers' instructions.
Data analysis
MICs of tigecycline and susceptibility categories based on the 2011 EUCAST interpretive criteria (susceptible, ≤1 mg/L; intermediate, 2 mg/L; and resistant, .2 mg/L) by both methods (VTK and BMD) were recorded for all strains. Essential agreement was calculated as the percentage of isolates for which the VTK MIC was identical to or within plus or minus one doubling dilution of the BMD MIC value. Category agreement corresponded to the percentage of isolates having identical susceptibility category results with both testing methods. A very major error was recorded for isolates categorized as susceptible by VTK and resistant by BMD; a major error was recorded in case of an opposite result. All other errors were considered minor.
For the subset of isolates belonging to the ESBL-producing Enterobacteriaceae, the MIC distribution of tigecycline (including MIC 50 and MIC 90 values) and susceptibility rates were calculated for both methods. The data were also reported and analysed by species individually.
Results and discussion
The correlation data of the in vitro susceptibility results of tigecycline by VTK and by BMD are presented in Table 1 . Overall, the VTK automated system provided reliable tigecycline MIC results in comparison with the reference BMD method for E. coli (essential and category agreement rates of 97.2%). The minor and major error rates by the VTK method were low for the E. coli isolates (2.5% and 0.4%, respectively). On the other hand, these error rates averaged 36.4% and 3.7%, respectively, in the isolates belonging to Enterobacteriaceae species other than E. coli (n¼ 217). A very major error was found in one isolate of Serratia marcescens with an MIC value of 1 mg/L by VTK versus 4 mg/L by BMD. Overall, VTK yielded 2-to 4-fold higher MIC values compared with BMD for 73% of the non-E. coli species (n¼ 217). Consequently, higher MIC 50 and MIC 90 values were observed for these species, also explaining the lower category agreement (59%) and lower susceptibility rates (55%) obtained with the VTK method. However, it is difficult to find a clear explanation other than technical issues of VTK (differences in growth rate or inoculum size between E. coli and non-E. coli species, generating different growth curves) for the much lower essential agreement rate obtained for non-E. coli species (81%) compared with the one obtained for E. coli isolates (97%). Similar discordances in tigecycline susceptibility testing results have also been observed for non-E. coli species in studies comparing BMD with other testing methods, such as Etest 8 or disc diffusion. Table 1 . By the reference BMD method, tigecycline displayed excellent activity against the vast majority of ESBL-positive isolates (susceptibility rate of 92.8% by EUCAST interpretative criteria). However, when analysing the MIC results by species, tigecycline indeed appeared very active in vitro against E. coli isolates (MIC 90 of 0.5 mg/L by the BMD method), while it was much less potent against other Enterobacteriaceae species (MIC 90 of 2 mg/L; 81.6% susceptibility versus 100% susceptibility in E. coli; P,0.0001). The lower susceptibility rates to tigecycline of non-E. coli Enterobacteriaceae species are compatible with the MIC distribution of susceptible wild-type strains, which were shown to display higher epidemiological cut-off (ECOFF) values for Klebsiella pneumoniae, Enterobacter aerogenes and Enterobacter cloacae (2 mg/L, which falls into the intermediate susceptibility category according to EUCAST criteria) compared with the ECOFF value for E. coli (1 mg/L).
2 While nearly no difference in MIC values was observed between both methods for E. coli (tigecycline MIC 90 of 0.5 mg/L for both VTK and BMD), the MIC 90 values of tigecycline for the non-E. coli species were 2-to 4-fold higher by VTK compared with by the BMD method, and this resulted in a substantial decrease in the tigecycline susceptibility rate down to 48.4% according to the 2011 EUCAST interpretive criteria. In one other multicentre survey, Rodriguez-Villalobos et al. 10 reported a rather low susceptibility rate of 67% to tigecycline amongst ESBL-producing Enterobacteriaceae isolates, but in this study the tigecycline MIC was determined by the Etest method, which has also previously been reported as overestimating the values of tigecycline MICs. 5, 8 The tigecycline susceptibility testing results against an additional set of 97 non-ESBL-producing Enterobacteriaceae isolates are shown in Table 2 . Among others, these isolates included 51 strains displaying various resistance mechanisms to b-lactams other than ESBLs (11 narrow-spectrum penicillinases, 5 K-OXY/K-1 penicillinase overproducers, 27 chromosomal AmpC overproducers and 8 plasmidic AmpC producers) and 29 carbapenemnon-susceptible strains (6 OXA-48, 4 KPC-2, 4 NDM-1, 4 VIM-1 and 1 VIM-4 carbapenemase producers, and 10 strains resistant by porin deficiency or reduced permeability). Overall, 73 (75.3%) and 86 (88.7%) of the 97 isolates were tested susceptible by VTK and by BMD, respectively. A lower number of tigecycline-susceptible isolates was again observed in this subset of isolates within the group of non-E. coli species isolates, whatever the testing method considered {VTK [45/68 (66%)]; BMD method [57/68 (84%)]}, while all 29 E. coli isolates tested susceptible by BMD and all but one were susceptible by VTK. With regard to the carbapenem-non-susceptible Enterobacteriaceae isolates, the proportion of isolates susceptible to tigecycline using the EUCAST breakpoint criteria was also lower by VTK (16/29; 55%) than by BMD (23/29; 79%). Livermore et al.
11 recently reported low tigecycline susceptibility rates (47% of 81 isolates tested by agar dilution method) among carbapenemaseproducing Enterobacteriaceae and lower rates of tigecycline susceptibility in non-E. coli species were observed as well. The latter finding appears worrisome, since tigecycline is one among the few other clinically available alternatives against such multiresistant pathogens.
In summary, our study clearly questions the performance of the VTK automated system for reliable determination of the susceptibility of Enterobacteriaceae species other than E. coli to tigecycline. We strongly recommend that Enterobacteriaceae isolates reported as non-susceptible to tigecycline by VTK should be tested for confirmation with the BMD method in order to avoid the misclassification of results that could remove tigecycline as an important therapeutic option in infected patients. 
